EUVIMEDEUVIMED entdecken
Crossref

Discovery and Structure–Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection

Georg Rueedi iD, Philippe Panchaud iD, Astrid Friedli, Jean-Luc Specklin, Christian Hubschwerlen, Anne-Catherine Blumstein, Patrick Caspers, Michel Enderlin-Paput, Loïc Jacob, Christopher Kohl iD, Hans H Locher, Philippe Pfaff und 3 weitere

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c00558 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Georg Rueedi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Idorsia Pharmaceuticals Ltd, CH-4123 Allschwil, Switzerland. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Clostridioides difficile, Clostridium Infections, Microbial Sensitivity Tests. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clostridioides difficile (C. difficile) is one of the leading causes of healthcare-associated infections worldwide. The increasing incidence of strains resistant to currently available therapies highlights the need for alternative treatment options with a novel mode of action. Oxazolidinones that are connected to a quinolone moiety with a pyrrolidine linker, such as compound 1, are reported to exhibit potent broadspectrum antibacterial activity. In an effort to optimize this class of compounds for the treatment of C. difficile infection (CDI), we have identified cadazolid (9), a first-in-class quinoxolidinone antibiotic, which is a potent inhibitor of C. difficile protein synthesis. In order to achieve narrow-spectrum coverage of clinically most relevant strains without affecting the gut microbiota, an emphasis was placed on abolishing activity against commensals of the intestinal microbiome while retaining good coverage of pathogenic C. difficile, including hypervirulent and epidemic strains.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsClostridioides difficileClostridium InfectionsMicrobial Sensitivity TestsStructure-Activity RelationshipAnimalsHumansDrug DiscoveryGastrointestinal MicrobiomeMiceOxazolidinones

Substanzen

Anti-Bacterial AgentscadazolidOxazolidinones

Autor:innen und Institutionen

  • Idorsia Pharmaceuticals Ltd, CH-4123 Allschwil, Switzerland.

ORCID-Profile: Georg Rueedi, Philippe Panchaud, Christopher Kohl

Zitieren

APA

Rueedi, G., Panchaud, P., Friedli, A., Specklin, J. L., Hubschwerlen, C., Blumstein, A. C., Caspers, P., Enderlin-Paput, M., Jacob, L., Kohl, C., Locher, H. H., Pfaff, P., Schmitt, C., Seiler, P., & Ritz, D. (2024). Discovery and Structure–Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00558

Vancouver

Rueedi G, Panchaud P, Friedli A, Specklin JL, Hubschwerlen C, Blumstein AC, et al. Discovery and Structure–Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00558

BibTeX
@article{Rueedi2024,
  author = {Rueedi, Georg and Panchaud, Philippe and Friedli, Astrid and Specklin, Jean-Luc and Hubschwerlen, Christian and Blumstein, Anne-Catherine and Caspers, Patrick and Enderlin-Paput, Michel and Jacob, Loïc and Kohl, Christopher and Locher, Hans H and Pfaff, Philippe and Schmitt, Christine and Seiler, Peter and Ritz, Daniel},
  title = {Discovery and Structure–Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00558}
}
Kostenlos starten →